SGT-53 + docetaxel

**SGT-53 + docetaxel** is a combination therapy consisting of SGT-53—a targeted, tumor-specific, liposomal nanoparticle delivering wild-type (wt) human p53 gene—and docetaxel, a well-established taxane-class cytotoxic chemotherapeutic. SGT-53 uses an anti-transferrin receptor single-chain antibody fragment for targeting, encapsulates the wt p53 cDNA in plasmid form, and is formulated with a cationic liposome. This design allows intravenous systemic administration to deliver p53 to tumor cells, restoring tumor suppressor function and sensitizing tumor cells to chemotherapy and immunotherapy. Docetaxel disrupts microtubule function and arrests cells in mitosis. Preclinical and clinical data show that SGT-53 enhances the efficacy of docetaxel in advanced solid tumors, with evidence for tumor targeting, immune modulation, and partial responses in patients. Developed primarily for advanced malignancies, including solid tumors and glioblastoma, this combination has demonstrated safety and tolerability in early-phase clinical trials[1][2][3][4][5].

Other names

p53-gene-therapy-SynerGenep-53-gene-therapy-SynerGenep 53-gene-therapy-SynerGeneSGT-53 plus docetaxelSGT53 plus docetaxelSGT 53 plus docetaxelSGT-53 and docetaxelSGT53 and docetaxelSGT 53 and docetaxel